MATTER, the premier healthcare incubator and innovation hub, with support from the Lundbeck US Charitable Fund, a corporate foundation dedicated to responsibly giving back to the community, has selected machineMD as one of five startups to participate in the Advancing Brain Health Innovation Challenge. The challenge is designed to address barriers to redefine care for people with rare neurological diseases.
"Oculometrics is one of the most promising domains for objectively measuring visual signs and symptoms that people frequently encounter when living with rare neurological diseases," said Avantika Naidu, PD, PhD, VP Business Development at machineMD. "I'm grateful to MATTER and the Lundbeck US Charitable Fund for initiating this collaborative approach to improve diagnosis and care."
Every year, millions of people with rare neurological diseases encounter challenges in receiving timely and accurate diagnoses.1 These challenges arise due to the complex nature of rare neurological disorders, limited specialized resources and a general lack of public awareness.1 However, recent advancements in medical science and a growing commitment to improving the healthcare journey offer promising early steps toward overcoming these obstacles. With continued progress, enhanced diagnostic and treatment pathways have the potential to deliver quicker answers, improve quality of life and achieve better outcomes for individuals with rare neurological conditions.1
Specialized care is key for those with rare neurological diseases, yet patients often face long waits for appointments or must travel long distances to see qualified providers.2 Newly emerging approaches can make care more accessible for those affected by these conditions. Innovations in telehealth, for example, can allow patients to connect with specialists, especially benefiting those in rural or underserved areas.2 By enhancing referral systems and expanding telehealth options, the goal is to help patients with rare neurological diseases access the care they need, where and when they need it.
At MATTER, we believe collaboration is the best way to improve healthcare. The MATTER collaborative includes more than 1,000 current and alumni startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.
The Lundbeck US Charitable Fund is an independently managed nonprofit 501(c)(3) committed to responsibly and appropriately supporting organizations and programs that share our dedication to advancing brain health and transforming lives. The Lundbeck US Charitable Fund is wholly owned by H. Lundbeck A/S, a global pharmaceutical company specialized in brain diseases. For more than 70 years, Lundbeck has been at the forefront of neuroscience research, tirelessly dedicated to restoring brain health so every person can be their best.